Table 2.
The Distribution of Patients with Early Gastric Cancer
| Characteristic | WMD | PD | PCC | Mixed carcinoma | Total | p-value* | p-value† |
|---|---|---|---|---|---|---|---|
| No. of patients | 3,306 (63.8) | 335 (6.5) | 981 (18.9) | 557 (10.8) | 5,179 (100) | ||
| Age, yr | 65.2±10.0 | 61±12.6 | 53.2±11.9 | 55.5±12.1 | 61.6±11.9 | <0.001 | <0.001 |
| Sex | <0.001 | <0.001 | |||||
| Male | 2,484 (75.1) | 231 (69.0) | 453 (46.2) | 288 (51.7) | 3,456 (66.7) | ||
| Female | 822 (24.9) | 104 (31.0) | 528 (53.8) | 269 (48.3) | 1,723 (33.3) | ||
| Size of tumor, cm | 2.0±1.4 | 2.6±1.7 | 2.4±1.4 | 3.2±1.9 | 2.3±1.5 | <0.001 | <0.001 |
| Location | <0.001 | 0.014 | |||||
| Upper | 372 (11.3) | 60 (17.9) | 122 (12.4) | 67 (12.0) | 621 (12.0) | ||
| Middle | 488 (14.8) | 90 (26.9) | 267 (27.2) | 128 (23.0) | 973 (18.8) | ||
| Lower | 2,446 (74.0) | 185 (55.2) | 592 (60.3) | 362 (65.0) | 3,585 (69.2) | ||
| Lauren type | <0.001 | <0.001 | |||||
| Intestinal | 3,302 (99.9) | 166 (49.6) | 0 | 141 (25.3) | 3,609 (69.7) | ||
| Diffuse | 2 (0.1) | 157 (46.9) | 978 (99.7) | 327 (58.7) | 1,464 (28.3) | ||
| Mixed | 2 (0.1) | 12 (3.6) | 3 (0.3) | 89 (16.0) | 106 (2.0) | ||
| Treatment | <0.001 | <0.001 | |||||
| Endoscopic | 1,587 (48.0) | 39 (11.6) | 49 (5.0) | 35 (6.3) | 1,710 (33.0) | ||
| Operative | 1,719 (52.0) | 296 (88.4) | 932 (95.0) | 522 (93.7) | 3,469 (67.0) | ||
| Tumor appearance‡ | <0.001 | <0.001 | |||||
| 0-I | 125 (3.9) | 3 (0.9) | 2 (0.2) | 7 (1.3) | 137 (2.7) | ||
| 0-IIa | 667 (21.0) | 45 (14.1) | 57 (6.1) | 54 (9.7) | 823 (16.5) | ||
| 0-IIb | 424 (13.4) | 54 (16.9) | 232 (24.7) | 87 (15.7) | 797 (16.0) | ||
| 0-IIc | 1,925 (60.7) | 211 (65.9) | 636 (67.7) | 392 (70.8) | 3,164 (63.5) | ||
| 0-III | 32 (1.0) | 7 (2.2) | 12 (1.3) | 12 (2.2) | 63 (1.3) | ||
| Lymphatic invasion | 344 (10.7) | 69 (21.4) | 45 (4.8) | 74 (13.3) | 532 (10.6) | <0.001 | <0.001 |
| Venous invasion | 28 (0.9) | 4 (1.2) | 4 (0.4) | 2 (0.4) | 38 (0.8) | 0.246 | 0.177 |
| Perineural invasion | 37 (1.2) | 14 (4.3) | 51 (5.4) | 23 (4.1) | 125 (2.5) | <0.001 | 0.489 |
| T stage§ | <0.001 | <0.001 | |||||
| 1a | 2,252 (68.1) | 155 (46.3) | 647 (66.0) | 328 (58.9) | 3,382 (65.3) | ||
| 1b | 1,054 (31.9) | 180 (53.7) | 334 (34.0) | 229 (41.1) | 1,797 (34.7) | ||
| Node metastasis | <0.001 | <0.001 | |||||
| Negative | 3,110 (94.1) | 278 (83.0) | 881 (89.8) | 429 (77.0) | 4,698 (90.7) | ||
| Positive | 196 (5.9) | 57 (17.0) | 100 (10.2) | 128 (23.0) | 481 (9.3) | ||
| Distant metastasis | 0.666 | 0.929 | |||||
| Negative | 3,303 (99.9) | 334 (99.7) | 979 (99.8) | 556 (99.8) | 5,172 (99.9) | ||
| Positive | 3 (0.1) | 1 (0.3) | 2 (0.2) | 1 (0.2) | 7 (0.1) |
Data are presented as number (%) or mean±SD.
WMD, well-moderately differentiated; PD, poorly differentiated; PCC, poorly cohesive carcinoma.
*The p-values were calculated by Student t-test (for continuous variables) and the chi-square test (for categorical variables); †The p-values were calculated to compare the other three groups (except WMD) by Student t-test (for continuous variables) and the chi-square test (for categorical variables); ‡The total number was different because unknown or missing values were excluded from the percentage calculation; §The clinical stage was established according to the guidelines of the 8th American Joint Committee on Cancer.